Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
24/04/2026 10:00
Celltrion Inc 068270.KS: PLANS PHASE 3 CLINICAL TRIALS FOR KEYTRUDA BIOSIMILAR WITH 220 PATIENTS Source text: [ID:] Further company coverage: 068270.KS
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares